22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) at Dr. Essa Lab

22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) at Dr. Essa Lab

The 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) at Dr. Essa Lab is a highly specialized molecular cytogenetic test designed to detect chromosomal abnormalities associated with Ewing sarcoma. Ewing sarcoma is an aggressive, malignant small round blue cell tumor that primarily affects bone and soft tissue in children, adolescents, and young adults. Diagnosing this condition with high precision is critical because its clinical presentation and histological appearance can closely mimic other round cell malignancies, such as lymphoma, neuroblastoma, rhabdomyosarcoma, and osteosarcoma. This advanced diagnostic test utilizes Fluorescence In Situ Hybridization (FISH) technology to identify rearrangements involving the EWSR1 gene located on chromosome 22q12, which serves as the diagnostic hallmark of the Ewing sarcoma family of tumors.

Fluorescence In Situ Hybridization (FISH) is a powerful molecular pathology technique that allows clinical pathologists to visualize specific DNA sequences directly within tissue specimens. The test works by using fluorescently labeled single-stranded DNA probes that are complementary to the target sequences on chromosome 22q12. When these probes hybridize, or bind, to the patient’s tumor DNA, they emit distinct fluorescent signals that can be visualized under a specialized fluorescence microscope. In a normal cell, the signals remain intact or fused, indicating no chromosomal breakage. However, in the presence of a 22q12 rearrangement, the fluorescent signals separate or “break apart,” indicating a translocation. The most common translocation associated with Ewing sarcoma is t(11;22)(q24;q12), which fuses the EWSR1 gene on chromosome 22 with the FLI1 gene on chromosome 11, occurring in approximately 85% to 90% of cases. Other variant translocations, such as t(21;22)(q22;q12) involving the ERG gene, can also be detected through this comprehensive assay.

The clinical importance of the 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) at Dr. Essa Lab cannot be overstated. Accurate identification of the EWSR1 rearrangement is the gold standard for confirming a diagnosis of Ewing sarcoma. This confirmation is vital for oncologists to initiate the correct, highly aggressive therapeutic protocols, which typically include multi-agent chemotherapy, surgical resection, and radiation therapy. Dr. Essa Lab, a trusted leader in diagnostic services in Karachi, Pakistan, facilitates this advanced testing to ensure patients receive timely, accurate, and actionable diagnostic reports. By utilizing state-of-the-art molecular techniques and collaborating with premier academic reference laboratories like the Aga Khan University (AKU) diagnostic network, Dr. Essa Lab provides a seamless pathway from biopsy to definitive molecular diagnosis, helping clinicians make life-saving treatment decisions.

Clinical Procedure: What to Expect

Patient Preparation

Because the 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) test is performed on tissue specimens—typically formalin-fixed paraffin-embedded (FFPE) tissue blocks obtained from a previous biopsy or surgical resection—there is no direct physical preparation required from the patient at the time of laboratory processing. However, patients and healthcare providers should keep the following preparation guidelines in mind:

• Specimen Submission: Ensure that the primary tumor biopsy or surgical resection specimen is properly preserved in 10% neutral buffered formalin and embedded in paraffin. The quality of the tissue block directly impacts the success of the FISH assay.
• Pathology Reports: Provide a copy of the initial histopathology report and any relevant radiological findings along with the test requisition form to assist the molecular pathologist in selecting the most representative tumor areas.
• No Fasting Required: Since the test is performed on an existing tissue sample, there are no dietary restrictions, fasting requirements, or medication adjustments necessary for the patient.
• Biopsy Coordination: If a fresh biopsy is required to obtain the tissue, the patient must follow the specific preparation instructions provided by their interventional radiologist or surgeon, which may include fasting or temporary cessation of blood-thinning medications.

During the Procedure

The laboratory workflow for the 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) at Dr. Essa Lab involves several highly controlled, technical steps performed by experienced molecular technologists and pathologists:

• Tissue Selection: A consultant pathologist reviews the hematoxylin and eosin (H&E) stained slides of the tumor tissue to identify the areas with the highest density of viable tumor cells and minimal necrosis.
• Sectioning and Deparaffinization: Thin sections (typically 4 to 5 micrometers) are cut from the paraffin block and mounted on positively charged glass slides. The slides are then heated and treated with chemical solvents to remove the paraffin wax.
• Pretreatment and Enzymatic Digestion: The tissue sections are subjected to heat and enzymatic digestion (usually with pepsin) to break down protein barriers, making the target nuclear DNA accessible to the fluorescent probes.
• Probe Application and Denaturation: A dual-color break-apart probe targeting the EWSR1 gene region on chromosome 22q12 is applied to the tissue. The slides are placed in a thermal cycler to denature both the probe and the target tissue DNA, separating the double strands into single strands.
• Hybridization: The slides are incubated overnight at a controlled temperature (usually 37°C) to allow the fluorescent probes to bind specifically to their complementary sequences on the patient’s DNA.
• Post-Hybridization Washing: Unbound or non-specifically bound probes are washed away using stringent chemical solutions at precise temperatures to prevent background noise.
• Counterstaining and Visualization: The cell nuclei are counterstained with a blue fluorescent dye called DAPI. The slides are then examined under a high-power fluorescence microscope equipped with specialized filters for green, orange/red, and blue wavelengths.
• Signal Counting and Interpretation: A molecular specialist counts the fluorescent signal patterns in at least 50 to 100 non-overlapping tumor nuclei. The percentage of cells showing a rearranged (break-apart) pattern is calculated to determine if the sample is positive for the 22q12 rearrangement.

When is a 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) Performed?

Evaluating Primary Bone Tumors in Children and Young Adults

Physicians request this test when a pediatric or young adult patient presents with clinical and radiological signs of a primary bone malignancy. Ewing sarcoma typically manifests as localized bone pain, swelling, tenderness, and sometimes a palpable mass, often in the pelvis, femur, tibia, or chest wall. X-rays and MRI scans frequently reveal a destructive bone lesion with an “onion-skin” periosteal reaction. Because these clinical findings can overlap with osteosarcoma or osteomyelitis, performing the FISH test on the bone biopsy is essential to confirm the diagnosis of Ewing sarcoma.

Differentiating Small Round Blue Cell Tumors

Under a standard light microscope, Ewing sarcoma appears as a sheet of uniform, small, round, blue cells with scant cytoplasm. This histological appearance is shared by several other aggressive neoplasms, collectively known as small round blue cell tumors (SRBCTs). These include lymphoma, neuroblastoma, rhabdomyosarcoma, and synovial sarcoma. Because the treatment strategies and prognoses for these diseases differ drastically, pathologists utilize the 22q12 FISH assay to definitively isolate Ewing sarcoma from its histological mimics based on its unique genetic signature.

Investigating Extraosseous Soft Tissue Masses

Although Ewing sarcoma most commonly originates in bone, it can also arise in the deep soft tissues of the extremities, retroperitoneum, or trunk—a condition known as extraosseous Ewing sarcoma. These soft tissue masses can be highly challenging to diagnose because they lack the characteristic bone involvement on initial imaging. When a biopsy of a soft tissue mass reveals round cell morphology, clinicians order the 22q12 rearrangement test to determine if the tumor belongs to the Ewing sarcoma family, ensuring the patient is directed to the appropriate oncological pathway.

Assessing Atypical Presentations or Metastatic Disease

In cases where a patient presents with metastatic disease of unknown primary origin, or when the tumor exhibits atypical histological features (such as spindle cell or large cell variants), standard immunohistochemical staining may yield ambiguous results. In these complex clinical scenarios, finding the EWSR1 (22q12) rearrangement via FISH provides definitive diagnostic clarity. Confirming the molecular lineage of the metastatic cells is crucial for establishing the primary diagnosis and planning systemic therapy.

Guiding Targeted and Protocol-Based Oncological Therapy

Modern oncological protocols for Ewing sarcoma are highly standardized and intensive, requiring a confirmed diagnosis before initiation. Because these treatments carry significant side effects, including cardiotoxicity and secondary malignancies, clinicians must have absolute diagnostic certainty. The 22q12 FISH test provides this certainty, allowing the oncology team to confidently prescribe high-dose chemotherapy regimens and plan local control measures like limb-sparing surgery or targeted radiotherapy.

What Does a 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) Detect?

The 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) test is designed to detect a wide range of cytogenetic and technical parameters within the tumor sample. Specifically, the assay evaluates and detects:

• The presence of a classic break-apart signal pattern, indicating a rearrangement of the EWSR1 gene at the 22q12 locus.
• The absence of any rearrangement, confirming a normal, intact 22q12 locus in the evaluated cells.
• The exact percentage of tumor nuclei displaying the rearranged signal pattern.
• The presence of the classic t(11;22)(q24;q12) translocation signal configuration.
• Alternative translocation patterns involving other partner chromosomes, such as chromosome 21 (ERG gene).
• Atypical signal patterns, such as single red or single green signals, which may indicate deletions or complex rearrangements.
• The copy number of the EWSR1 gene, identifying potential gene amplification or locus duplication.
• Monosomy of chromosome 22, characterized by the loss of one set of signals in the tumor nuclei.
• Polyploidy or multi-signal patterns, indicating chromosomal instability or whole-genome duplication within the tumor cells.
• The adequacy of the tumor specimen, ensuring there is sufficient viable tumor cellularity for a reliable analysis.
• The level of background autofluorescence, which could interfere with signal interpretation.
• The hybridization efficiency of the fluorescent probes within the tissue sections.
• The presence of normal internal control cells (such as lymphocytes or stromal cells) showing normal fused signal patterns.
• Co-existing chromosomal deletions near the 22q12 region.
• Clonal heterogeneity, indicating whether only a subpopulation of tumor cells carries the rearrangement.
• Technical artifacts, such as signal overlapping or nuclear truncation, which are accounted for during mathematical analysis.
• The impact of tissue decalcification on DNA integrity, particularly in bone biopsy samples.
• Correlation of fluorescent signals with the histopathological features of the tumor.
• The presence of atypical fusion partners that may influence clinical behavior or treatment response.
• The diagnostic confirmation of the Ewing sarcoma family of tumors based on molecular criteria.

Turnaround Time and Report Access at Dr. Essa Lab

The 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) is a highly specialized molecular cytogenetic assay that requires meticulous laboratory processing, hybridization, and expert interpretation by a consultant pathologist. At Dr. Essa Lab, the typical turnaround time for this advanced molecular test is approximately 7 to 10 working days. This timeline ensures that the tissue undergoes optimal pretreatment, overnight hybridization, and detailed microscopic analysis to deliver the highest level of diagnostic accuracy.

Patients and referring physicians can easily access reports through Dr. Essa Lab’s secure digital infrastructure. Once the consultant pathologist signs off on the final report, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be downloaded directly from the official Dr. Essa Lab website using the unique lab ID and password provided on the receipt. Additionally, reports can be accessed via the Dr. Essa Lab mobile application or collected in person from any of their convenient diagnostic centers located across Karachi and other major cities in Pakistan.

22Q12 Rearrangemen in Ewing sarcoma by fish (AKU) Findings Overview

The following table outlines the key parameters evaluated during the FISH analysis, along with their corresponding normal and abnormal clinical findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
EWSR1 (22q12) Rearrangement Status	Negative (No rearrangement detected)	Positive (EWSR1 gene rearrangement detected)
Signal Pattern (Break-Apart Probe)	Fused orange/green (yellow) signals	Separated orange and green signals (break-apart)
Percentage of Positive Nuclei	Below the established laboratory threshold (typically <10%)	Above the diagnostic threshold (typically >10% to 100%)
EWSR1 Gene Copy Number	Two fused signals per nucleus (diploid)	Amplification (multiple signals) or deletion (single signal)
Tumor Cellularity	Adequate viable tumor cells present for evaluation	Inadequate cellularity, extensive necrosis, or non-representative tissue
Control Cell Hybridization	Normal fused signals in non-neoplastic cells	Failure of hybridization in control cells (technical invalidity)
Tissue Fixation Quality	Excellent DNA preservation with clear, bright signals	Weak or diffuse signals due to poor fixation or over-decalcification
Inferred Fusion Partner	None (normal gene configuration)	t(11;22) EWSR1-FLI1 or t(21;22) EWSR1-ERG translocations

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for 22Q12 Rearrangemen in Ewing sarcoma by fish (AKU)?

• Experienced Healthcare Professionals: Dr. Essa Lab boasts a team of highly qualified pathologists, molecular biologists, and laboratory technologists specializing in advanced cytogenetics.
• Patient-Focused Care: The laboratory is dedicated to providing compassionate support, clear communication, and professional guidance to patients and their families during critical diagnostic journeys.
• Quality Diagnostic Services: Dr. Essa Lab adheres to strict international quality control standards, ensuring that molecular assays like FISH are performed with maximum precision.
• Professional Reporting: Reports are detailed, comprehensive, and structured to provide oncologists with the precise molecular data needed to formulate treatment plans.
• Modern Diagnostic Approach: Utilizing state-of-the-art fluorescence microscopy and hybridization equipment, the lab ensures highly reliable signal detection.
• Comfortable Environment: From sample submission to report collection, Dr. Essa Lab provides a professional, clean, and welcoming environment for all patients.
• Convenient Location: With an extensive network of collection centers across Karachi and Pakistan, patients can easily submit samples and collect reports.
• Commitment to Accurate Diagnosis: Dr. Essa Lab’s collaboration with leading academic reference networks like AKU ensures access to the highest tier of specialized medical testing.